Hopkins study suggests treatments for 'wet' AMD keep elderly drivers behind the wheel

Small, limited study with ranibizumab did not directly assess driving safety or skills

2012-10-02

(Press-News.org) The advanced neovascular, or "wet," form of age-related macular degeneration (AMD), left untreated, is the most common cause of vision loss among the elderly and a leading reason for their loss of driving privileges. But results of a new study, published in the online version of the journal Ophthalmology, suggest that monthly injections of ranibizumab improve eye chart test results required for a driver's license, build driver confidence and keep those with AMD driving longer.

The wet form of AMD is marked by the abnormal scarring and leaking of new blood vessels in the macula, or center of the retina, the light-sensitive layer of the eye used for driving, reading or recognizing faces. Treatment with ranibizumab, a drug made partly from a human monoclonal antibody fragment, is done by injecting it monthly (or as needed with frequent evaluations) into the middle of the eye with a tiny needle about the diameter of a hair. The medicine eliminates or slows new scar and leaking blood vessel formation.

"Driving is an important measure of independence and quality of life for many people in the United States. Participants with wet AMD in our study perceived that they were not driving because of their diminished eyesight," said senior author, Neil M. Bressler, M.D., the James P. Gills Professor of Ophthalmology and chief of the Retina Division at the Wilmer Eye Institute at Johns Hopkins Medicine. "Our study, believed to be the first of its kind to look at whether outcomes relevant to driving improve with treatment, suggests that monthly injections of ranibizumab may be an extremely helpful option in allowing the elderly to continue driving."

During the phase III, multicentered, randomized two-year clinical trial, researchers used a 25-item National Eye Institute Visual Function Questionnaire to measure study participants' driving ability, perception and self-reported driving status in two distinct studies. Investigators also conducted monthly assessments, over a two-year period, of the best corrected vision in each eye of 1,126 patients enrolled in these studies that evaluated treatments for AMD. One study compared results for those receiving ranibizumab versus sham (fake) injections; the second compared results of ranibizumab injections versus photodynamic (laser) therapy (PDT) that can seal abnormally leaking blood vessels.

Based on the results of two previous reports from these studies, ranibizumab was better than sham and PDT treatments with respect to avoiding loss of vision when treating patients with an eye affected by wet AMD. This new analysis of those trials by Bressler and colleagues looked beyond the results of these treatments on reading an eye chart to clinically relevant outcomes regarding the impact of this treatment on driving in three ways: treatment versus no treatment in those who said they were driving or not driving at the beginning and end of the study; treatment versus no treatment in participants who had vision at the beginning and end of the study that would qualify them for an unrestricted driver's license in at least 45 of the U.S. states; and a standardized questionnaire assessing the patients' own perception about the level of difficulty driving in difficult conditions such as rain or fog or at night. The 45 states all require correctable vision of at least 20/40 in one eye to qualify for an unrestricted driver's license.

"What the study showed was that 85 percent of participants in the ranibizumab versus sham study and 88 percent in the ranibizumab versus PDT study read the eye chart better also achieved the level of vision required for an unrestricted license and in turn had greater confidence in driving," noted Bressler. The researchers cautioned that more research is needed to determine whether driving skills or driving safety are actually maintained or improved, and whether they match up with patient perceptions of their abilities reported on the questionnaire.

"Our study has limitations because these two studies were not designed to directly assess the impact of ranibizumab on driving, and because there was just a small number of patients in the groups that were analyzed relative to the hundreds of thousands of patients affected by the wet form of AMD each year around the world," Bressler stated. "One of our next steps is to look at these same outcomes when treatment is given for diabetic macular edema, swelling at the center of the retina as a result of diabetes, the most common cause of vision impairment in working-age adults in the U.S. and abroad."

### Other researchers in the study included Genentech consultants Tom S. Chang, M.D., from the Retina Institute of California; Rohit Varma, M.D., M.P.H., Doheny Eye Center; Ivan J. Suñer, M.D., Retina Associates of Florida; Paul Lee, M.D., Duke Eye Center, Duke University School of Medicine, Durham, N.C.; Chantal M. Dolan, Ph.D., Genentech, Inc., San Francisco; James Ward, Ph.D., Genentech, Inc., San Francisco; Tsontcho Ianchulev, M.D., Ph.D., affiliated with the University of California, San Francisco and Jennifer T. Fine, Sc.D., Transcend Medical, Menlo Park, Calif.

Neil M. Bressler, M.D., receives funding support from Allergan, Bausch & Lomb, Carl Zeiss Meditec, Genentech (which makes ranibizumab and markets it in the United States under the name Lucentis), Notal Vision, Inc., Novartis (which markets ranibizumab outside of the United States), Othera, QLT, Regeneron (which makes aflibercept and markets it in the United States under the name Eylea and competes directly with ranibizumab), and Steba Pharmaceuticals for sponsored projects by the Department of Ophthalmology. Bressler receives salary support for these sponsored projects; the terms of these projects are negotiated and administered by JHU's Office of Research Administration. Under JHU's policy, support for the costs of research, administered by the institution, does not constitute a conflict of interest.

ELSE PRESS RELEASES FROM THIS DATE:

New findings on the workings of the inner ear

2012-10-02

The sensory cells of the inner ear have tiny hairs called stereocilia that play a critical part in hearing. It has long been known that these stereocilia move sideways back and forth in a wave-like motion when stimulated by a sound wave. After having designed a microscope to observe these movements, a research team at Karolinska Institutet in Sweden has discovered that the hairs not only move sideways but also change in length. The discovery, which was made in collaboration with scientists at Baylor College of Medicine in Texas, USA provides new fundamental knowledge ...

New research measures the cost of getting cleaner air

2012-10-02

Extensive environmental regulations have brought cleaner air and health improvements to the United States, but they also have increased the cost of manufacturing and reduced industrial productivity, according to a study by economists at the University of Chicago and MIT. Some economists have suggested that the regulations encouraged companies to become more efficient, thus reducing costs at upgraded plants. But in a paper published by the National Bureau of Economic Research, three economists contend that the regulations led to a 4.8 percent decline in productivity and ...

Study: An apple a day lowers level of blood chemical linked to hardening of the arteries

2012-10-02

COLUMBUS, Ohio – Eating an apple a day might in fact help keep the cardiologist away, new research suggests. In a study of healthy, middle-aged adults, consumption of one apple a day for four weeks lowered by 40 percent blood levels of a substance linked to hardening of the arteries. Taking capsules containing polyphenols, a type of antioxidant found in apples, had a similar, but not as large, effect. The study, funded by an apple industry group, found that the apples lowered blood levels of oxidized LDL -- low-density lipoprotein, the "bad" cholesterol. When LDL ...

Among voters lacking strong party preferences, Obama faces 20% handicap due to race bias

2012-10-02

An online study of eligible voters around the country revealed that the preference for whites over blacks is the strongest in the least politically-partisan voters. Among these voters, race biases against Barack Obama could produce as much as a 20 percent gap in the popular vote in a contest that would otherwise be equal. "Although they may not determine the election outcome, race biases are having a strong anti-Obama effect among the least politically partisan voters," said Anthony Greenwald, a University of Washington psychology professor who conducted the survey. "If ...

New research model to aid search for degenerative disease cures

2012-10-02

Irvine, Calif., Oct. 2, 2012 — Efforts to treat disorders like Lou Gehrig's disease, Paget's disease, inclusion body myopathy and dementia will receive a considerable boost from a new research model created by UC Irvine scientists. The team, led by pediatrician Dr. Virginia Kimonis, has developed a genetically modified mouse that exhibits many of the clinical features of human diseases largely triggered by mutations in the valosin-containing protein. The mouse model will let researchers study how these now-incurable, degenerative disorders progress in vivo and will ...

Quantum causal relations: A causes B causes A

2012-10-02

This press release is available in German. One of the most deeply rooted concepts in science and in our everyday life is causality; the idea that events in the present are caused by events in the past and, in turn, act as causes for what happens in the future. If an event A is a cause of an effect B, then B cannot be a cause of A. Now theoretical physicists from the University of Vienna and the Université Libre de Bruxelles have shown that in quantum mechanics it is possible to conceive situations in which a single event can be both, a cause and an effect of another one. ...

Ames Laboratory finds ordered atoms in glass materials

2012-10-02

Scientists at the U.S. Department of Energy's Ames Laboratory have discovered the underlying order in metallic glasses, which may hold the key to the ability to create new high-tech alloys with specific properties. Glass materials may have a far less randomly arranged structure than formerly thought. Over the years, the ideas of how metallic glasses form have been evolving, from just a random packing, to very small ordered clusters, to realizing that longer range chemical and topological order exists. But by studying the structure of a metallic glass alloy formed ...

Use of EHR associated with improvements in outcomes for patients with diabetes

2012-10-02

OAKLAND, Calif., October 1, 2012 — Use of electronic health records was associated with improved drug-treatment intensification, monitoring, and risk-factor control among patients with diabetes, according to a new Kaiser Permanente study. In the study, which appears in the current issue of Annals of Internal Medicine, researchers also noted greater improvements among patients with poorer control of their diabetes and lipids. The findings provide an important contribution to the evidence base by demonstrating that, for the first time in a large population, EHRs help clinicians ...

Study examines safety of quadrivalent HPV vaccine given to females

2012-10-02

CHICAGO – A study of girls and young women in California suggests that the quadrivalent human papillomavirus vaccine (HPV4) appeared to be associated with syncope (fainting) on the day of vaccination and skin infections in the two weeks after vaccination, according to a report published Online First by Archives of Pediatrics & Adolescent Medicine, a JAMA Network publication. Human papillomavirus (HPV) is a family of small DNA viruses and infections with this viral family are the most commonly detected sexually transmitted infections in women. While most of these infections ...

Psychiatric disorders persist after youths leave detention

2012-10-02

CHICAGO --- It was a study everyone thought couldn't be done -- tracking, locating and interviewing nearly 2,000 youths up to five years after they were released from juvenile detention in Chicago to assess their mental health. But a team of intrepid Northwestern Medicine researchers found the young men and women and traveled anywhere necessary to interview them. Many were interviewed after they returned home. Others, however, were interviewed in less conventional locations -- a dancer on a break from her job in a nightclub, a woman in her boyfriend's garbage truck or ...

LAST 30 PRESS RELEASES:

CMD-OPT model enables the discovery of a potent and selective RIPK2 inhibitor as preclinical candidate for the treatment of acute liver injury

Melatonin receptor 1a alleviates sleep fragmentation-aggravated testicular injury in T2DM by suppression of TAB1/TAK1 complex through FGFR1

Single-cell RNA sequencing reveals Shen-Bai-Jie-Du decoction retards colorectal tumorigenesis by regulating the TMEM131–TNF signaling pathway-mediated differentiation of immunosuppressive dendritic ce